Decisions

On the 30th of January 2019 the Danish Competition Council (”DCC”) ruled in a case concerning Falck’s (Denmark's largest provider of ambulance services) abuse of dominant position by deciding and implementing an exclusionary strategy which aimed at excluding Falck’s competitor BIOS from the market.

On 19 March 2018 the Danish Competition and Consumer Authority (hereinafter “DCCA”) received a complete notification of Tryg Forsikring A/S’ (hereinafter “Tryg”) acquisition of sole control of Forsikrings-Aktieselskabet Alka (hereinafter “Alka”).

On the 29th of August 2018 the Danish Competition Council (“DCC”) ruled in a case concerning Teller’s (a merchant acquirer) abuse of dominant position by use of rebates conditional on exclusivity and provisions regarding exclusivity. Teller’s agreements with some of the company’s largest customers contained provisions which had a loyalty enhancing effect and could foreclose competitors’ access to the market.

On 10 April 2017 the Danish Competition and Consumer Authority (“DCCA”) received a complete notification of Danica Pension’s (“Danica”) acquisition of sole control of SEB Pensionsforsikring A/S and SEB Administration A/S (hereby after together referred to as ”SEB”).

On 13 November 2017 the Danish Competition and Consumer Authority (hereinafter “DCCA”) received a complete notification of GlobalConnect A/S’ (hereinafter “GlobalConnect”) acquisition of sole control of Nianet A/S (hereinafter “Nianet”).

On February 28, 2018, The Danish Competition Council (DCC) has found that, the association of passenger carriers Økonomisk Forening for Persontransport (“ØFP”, in English “Economic Association of Passenger Carriers”) has infringed Section 6 of the Danish Competition Act by coordinating its members’ bids on tenders where ØFP placed a bid. The DCC orders the association to end the infringement immediately and in the future refrain from any action having the same or similar object or effect.

On 31 January 2018, the Danish Competition Council (“DCC”) ruled in a case concerning CD Pharma’s (a pharmaceutical distributor) abuse of dominant position by charging unfair prices for the drug Syntocinon. Syntocinon contains oxytocin, which is an active substance given to pregnant women in connection with childbirth.